Tempest Therapeutics (TPST) Free Cash Flow (2012 - 2025)
Tempest Therapeutics (TPST) posted Free Cash Flow of -$3.6 million for Q4 2025, up 47.28% sequentially from -$6.8 million in Q3 2025, and up 64.8% YoY from -$2.2 million in Q4 2024.
Tempest Therapeutics (TPST) Free Cash Flow (2012 - 2025) Analysis & Trends
Tempest Therapeutics has reported Free Cash Flow for 14 years, with the latest figure at -$3.6 million in Q4 2025.
- Quarterly Free Cash Flow rose 64.8% year-over-year to -$3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$26.8 million (up 19.85% YoY) and the FY2025 annual result came in at -$26.8 million, up 19.85% from the prior year.
- Free Cash Flow grew to -$3.6 million in Q4 2025 per TPST's latest filing, from -$6.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $57000.0 in Q2 2021 and troughed at -$11.8 million in Q3 2021.
- A 5-year average of -$7.3 million and a median of -$7.2 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2021 and 2022: Free Cash Flow soared 96.55% in 2021, then tumbled 15028.07% in 2022.
- Over 5 years, Free Cash Flow stood at -$8.0 million in 2021, then grew by 14.69% to -$6.8 million in 2022, then climbed by 9.55% to -$6.2 million in 2023, then sank by 64.22% to -$10.2 million in 2024, then soared by 64.8% to -$3.6 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$3.6 million, -$6.8 million, and -$8.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 292.04 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -95.09 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 477.44 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 433.84 Mn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.57 Mn |
| Dec 31, 2025 | -3.57 Mn |
| Sep 30, 2025 | -6.78 Mn |
| Sep 30, 2025 | -6.78 Mn |
| Jun 30, 2025 | -8.43 Mn |
| Jun 30, 2025 | -8.43 Mn |
| Mar 31, 2025 | -8.04 Mn |
| Mar 31, 2025 | -8.04 Mn |
| Dec 31, 2024 | -10.15 Mn |
| Dec 31, 2024 | -10.15 Mn |
| Sep 30, 2024 | -10.20 Mn |
| Sep 30, 2024 | -10.20 Mn |
| Jun 30, 2024 | -5.76 Mn |
| Jun 30, 2024 | -5.76 Mn |
| Mar 31, 2024 | -7.35 Mn |
| Mar 31, 2024 | -7.35 Mn |
| Dec 31, 2023 | -6.18 Mn |
| Dec 31, 2023 | -6.18 Mn |
| Sep 30, 2023 | -6.49 Mn |
| Sep 30, 2023 | -6.49 Mn |